Angiotensin Ii Acetate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Angiotensin Ii Acetate |
| DrugBank ID | DB11842 |
| Brand Names (EU) | Giapreza |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 92.47% |
Approved Indication (EMA)
Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | 92.47% | DL |
| 2 | severe nonproliferative diabetic retinopathy | 92.04% | DL |
| 3 | exocrine pancreatic insufficiency | 91.29% | DL |
| 4 | diabetic retinopathy | 90.65% | DL |
| 5 | diabetic cataract | 89.45% | DL |
| 6 | nuclear senile cataract | 89.45% | DL |
| 7 | cortical cataract | 89.45% | DL |
| 8 | tetanic cataract | 89.42% | DL |
| 9 | immature cataract | 89.42% | DL |
| 10 | mature cataract | 89.42% | DL |
| 11 | craniostenosis cataract | 89.42% | DL |
| 12 | diabetes mellitus type 2 associated cataract | 89.42% | DL |
| 13 | senile cataract | 88.97% | DL |
| 14 | neuromuscular junction disease | 88.51% | DL |
| 15 | congenital myasthenic syndrome with tubular aggregates | 86.72% | DL |
| 16 | filariasis | 86.16% | DL |
| 17 | cecum villous adenoma | 85.05% | DL |
| 18 | rectosigmoid junction neoplasm | 85.05% | DL |
| 19 | cecum neuroendocrine tumor G1 | 84.99% | DL |
| 20 | cecal disease | 84.87% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.